Joseph T. Rabban III, MD, MPH

Harvard Medical School, MD, 1992-98, Medicine
Harvard School of Public Health, M.P.H., 1995-96, Medicine
University of California, San Francisco, Intern, 1998-99, General Surgery
University of California, San Francisco Resident, 1999-01, Anatomic Pathology
University of California, San Francisco Fellow, 2001-02, Surgical Pathology
University of California, San Francisco, Fellow, 2002-03, Cytopathology
Harvard Medical School Fellow, 2003-04, Gynecologic and Breast Pathology

• 2001-02
  Chief Resident, Anatomic Pathology, University of California, San Francisco
• 2003-04
  Clinical Fellow in Pathology, Harvard Medical School
• 2003-04
  Fellow in Pathology of Women's Cancer, Gillette Center for Women's Cancer, Massachusetts General Hospital
• 2003-04
  Graduate Assistant in Pathology, Massachusetts General Hospital
• 2004-present
  Deputy Director, Medical Student Pathology Elective, University of California, San Francisco
• 2004-present
  Associate Director, Surgical Pathology Fellowship, University of California, San Francisco
• 2004-2008
  Assistant Professor in Clinical Pathology, University of California, San Francisco
• 2008-present
  Associate Professor in Clinical Pathology, University of California, San Francisco

• Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ. Transitional Cell Metaplasia of Fallopian Tube Fimbriae: A Potential Mimic of Early Tubal Carcinoma in Risk Reduction Salpingo-oophorectomies From Women With BRCA Mutations. American Journal Surgical Pathology. 2008 Sep 30. [Epub ahead of print]
• Rabban JT, Chen YY. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma. Human Pathology. 2008; 39:175-83.
• Rabban JT, Zaloudek CJ. Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis. Pathology. 2007; 39:125-33
• Rabban J, Koerner F, Lerwill M. Solid Papillary Ductal Carcinoma In-Situ Versus Usual Ductal Hyperplasia in the Breast: A Potentially Difficult Distinction Resolved by Cytokeratin 5/6. Human Pathology 2006; 37: 787-93
• Rabban J, Swain R, Zaloudek C, Chase D, and Chen YY. Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential piftalls of myoepithelial markers. Modern Pathology, advance epub ahead of print; June 30, 2006
• Rabban J, Zaloudek C, Shekitka K, Tavassoli, F. Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. American Journal of Surgical Pathology 2005; 29: 1348-1355
• Rabban J, Dal Cin P, Oliva E. HMGA2 rearrangement in a case of vulvar aggressive angiomyxoma. International Journal of Gynecologic Pathology. in press, 2006
• Adler F, Rabban J, Yeh B, Qayyum A, Chen LM, Coakley F. Superficial endometrial spread of squamous cell cervical carcinoma: A diagnostic challenge at MRI. Journal of Computer Assisted Tomography, in press 2006
• Rabban J and Bell D. Current issues in the pathology of ovarian cancer. Journal of Reproductive Medicine. 2005; 50: 467-474
• Rabban J and Zaloudek C. Ovarian yolk sac tumors. Pathology Case Reviews 2006; 11: 50-57
• Rabban J and Zaloudek C. Vulvar Paget disease. Pathology Case Reviews 2005; 10:41-45
• Zaloudek C and Rabban J. Differentiated vulvar intraepithelial neoplasia (VIN): An underrecognized form of high-grade VIN associated with keratinizing squamous cell carcinoma of the vulva. Pathology Case Reviews 2005; 10:35-40
• Rabban J, Meng M, Yeh B, Koppie T, Ferrell L, Stoller M. Kidney morcellation in laparoscopic nephrectomy for tumor: recommendations for specimen sampling and pathologic tumor staging. American Journal of Surgical Pathology, 2001; 25: 1158-1166